Pembrolizumab与糖尿病:一例转移性黑色素瘤患者的糖尿病酮症酸中毒

IF 0.4 Q4 ENDOCRINOLOGY & METABOLISM
Songo Lolomari, S. Thayyil, M. Kong
{"title":"Pembrolizumab与糖尿病:一例转移性黑色素瘤患者的糖尿病酮症酸中毒","authors":"Songo Lolomari, S. Thayyil, M. Kong","doi":"10.15277/bjd.2023.410","DOIUrl":null,"url":null,"abstract":"Introduction The advent of immunotherapy has revolutionised the management of certain malignancies, and its use has increased over the past decade. Monoclonal antibody therapies known as checkpoint inhibitors work by enhancing the immune response against malignant cells by blocking the pathways that inhibit T-cell regulation. Checkpoint inhibitors can be administered alone or in combination as an intravenous infusion every 3-6 weeks for a maximum of two years. However, about 10% of patients may experience endocrine adverse effects. Thyroid disease and hypophysitis are those most commonly encountered; there are also reports of diabetes mellitus and primary adrenal insufficiency as well as rarer endocrinopathies. Pembrolizumab, an immune checkpoint inhibitor, received FDA approval in 2014 for advanced melanoma, and in 2015 for metastatic non-small cell lung cancer. It is also approved for recurrent/metastatic head and neck cancer, and for refractory classical Hodgkin’s lymphoma. We report the case of a 75-year-old man who developed new-onset diabetes mellitus and diabetic ketoacidosis while undergoing pembrolizumab chemotherapy for metastatic melanoma. He was not taking steroids.","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma\",\"authors\":\"Songo Lolomari, S. Thayyil, M. Kong\",\"doi\":\"10.15277/bjd.2023.410\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction The advent of immunotherapy has revolutionised the management of certain malignancies, and its use has increased over the past decade. Monoclonal antibody therapies known as checkpoint inhibitors work by enhancing the immune response against malignant cells by blocking the pathways that inhibit T-cell regulation. Checkpoint inhibitors can be administered alone or in combination as an intravenous infusion every 3-6 weeks for a maximum of two years. However, about 10% of patients may experience endocrine adverse effects. Thyroid disease and hypophysitis are those most commonly encountered; there are also reports of diabetes mellitus and primary adrenal insufficiency as well as rarer endocrinopathies. Pembrolizumab, an immune checkpoint inhibitor, received FDA approval in 2014 for advanced melanoma, and in 2015 for metastatic non-small cell lung cancer. It is also approved for recurrent/metastatic head and neck cancer, and for refractory classical Hodgkin’s lymphoma. We report the case of a 75-year-old man who developed new-onset diabetes mellitus and diabetic ketoacidosis while undergoing pembrolizumab chemotherapy for metastatic melanoma. He was not taking steroids.\",\"PeriodicalId\":42951,\"journal\":{\"name\":\"British Journal of Diabetes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15277/bjd.2023.410\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15277/bjd.2023.410","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

引言免疫疗法的出现彻底改变了某些恶性肿瘤的管理,在过去十年中,它的使用有所增加。被称为检查点抑制剂的单克隆抗体疗法通过阻断抑制T细胞调节的途径来增强对恶性细胞的免疫反应。检查点抑制剂可以单独给药,也可以每3-6周静脉滴注一次,最长两年。然而,大约10%的患者可能会出现内分泌不良反应。甲状腺疾病和垂体炎是最常见的疾病;也有糖尿病和原发性肾上腺功能不全以及罕见的内分泌疾病的报道。Pembrolizumab是一种免疫检查点抑制剂,于2014年获得FDA对晚期黑色素瘤的批准,并于2015年获得对转移性非小细胞肺癌癌症的批准。它还被批准用于复发/转移性癌症和难治性经典霍奇金淋巴瘤。我们报告了一例75岁的男性在接受pembrolizumab化疗治疗转移性黑色素瘤时出现新发糖尿病和糖尿病酮症酸中毒。他没有服用类固醇。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma
Introduction The advent of immunotherapy has revolutionised the management of certain malignancies, and its use has increased over the past decade. Monoclonal antibody therapies known as checkpoint inhibitors work by enhancing the immune response against malignant cells by blocking the pathways that inhibit T-cell regulation. Checkpoint inhibitors can be administered alone or in combination as an intravenous infusion every 3-6 weeks for a maximum of two years. However, about 10% of patients may experience endocrine adverse effects. Thyroid disease and hypophysitis are those most commonly encountered; there are also reports of diabetes mellitus and primary adrenal insufficiency as well as rarer endocrinopathies. Pembrolizumab, an immune checkpoint inhibitor, received FDA approval in 2014 for advanced melanoma, and in 2015 for metastatic non-small cell lung cancer. It is also approved for recurrent/metastatic head and neck cancer, and for refractory classical Hodgkin’s lymphoma. We report the case of a 75-year-old man who developed new-onset diabetes mellitus and diabetic ketoacidosis while undergoing pembrolizumab chemotherapy for metastatic melanoma. He was not taking steroids.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
British Journal of Diabetes
British Journal of Diabetes ENDOCRINOLOGY & METABOLISM-
自引率
16.70%
发文量
15
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信